GSA Capital Partners’s Century Therapeutics IPSC Stock Holding History

GSA Capital Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$295K	Buy	120,598 +43,762	+57%	+$100K	0.02%	1314
2026 Q1	$174K	Sell	76,836 -256,363	-77%	-$539K	0.01%	1485
2025 Q4	$331K	Sell	333,199 -270,280	-45%	-$165K	0.03%	1110
2025 Q3	$301K	Buy	603,479 +136,873	+29%	+$73.8K	0.03%	1195
2025 Q2	$261K	Buy	+466,606	New	+$250K	0.02%	1349
2023 Q3	–	Sell	-20,472	Closed	-$65K	–	1694
2023 Q2	$65K	Buy	+20,472	New	+$66K	0.01%	1410

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GSA Capital Partners's IPSC Position: Q2 2026 in Review

GSA Capital Partners increased its Century Therapeutics (IPSC) stake by 57% in Q2 2026, buying an estimated $100K and bringing the position to 120,598 shares worth $295K. The position accounts for 0.02% of the portfolio, ranked #1314.

GSA Capital Partners first reported a position in IPSC in Q2 2023 and has held it in 6 quarters since. The position peaked at $331K in Q4 2025. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

GSA Capital Partners held 120,598 shares of Century Therapeutics worth $295K as of Q2 2026.
GSA Capital Partners bought 43,762 Century Therapeutics shares in Q2 2026, an estimated $100K.
Century Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1314 holding.
GSA Capital Partners first reported a position in Century Therapeutics in Q2 2023 and has held it in 6 quarters since.
GSA Capital Partners's Century Therapeutics position peaked at $331K in Q4 2025.
99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.